Source: Health Canada shortage reports · Updated Jul 9, 2026
Some Bicalutamide products are in shortage in Canada (1 of 9 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer.
A hormone therapy used to treat prostate cancer.
Products affected
1 / 9
In shortage since
Jan 14, 2022
Reports on file
28
Talk to a pharmacist
Pharmacists can substitute an unaffected manufacturer's version, adjust strengths, and in most provinces adapt or renew a prescription on the spot.
Independent services, not affiliated with rxstat; referral fees may apply. Free options exist depending on your province. In an emergency call 911; free health advice at 811.
Shortage history
Shortage history (red bands = periods in shortage).
Reports by product
The DIN is printed on your prescription label.
Active shortage
ACH-BICALUTAMIDE
50MG · TABLET · ACCORD HEALTHCARE INC
DIN 02325985 · since Jan 14, 2022, no end estimate · Disruption of the manufacture of the drug.
Resolved
ACH-BICALUTAMIDE
50MG · TABLET · ACCORD HEALTHCARE INC
DIN 02325985 · ended Feb 2, 2026 · Requirements related to complying with good manufacturing practices.
Resolved
BICALUTAMIDE
50MG · TABLET · SANIS HEALTH INC
DIN 02519178 · ended Sep 3, 2025 · Disruption of the manufacture of the drug.
Discontinued
CASODEX
50MG · TABLET · ASTRAZENECA CANADA INC
DIN 02184478
Resolved
TEVA-BICALUTAMIDE
50MG · TABLET · TEVA CANADA LIMITED
DIN 02270226 · ended Feb 14, 2024 · Disruption of the manufacture of the drug.
Resolved
ACH-BICALUTAMIDE
50MG · TABLET · ACCORD HEALTHCARE INC
DIN 02325985 · ended Dec 14, 2023 · Demand increase for the drug.
Resolved
PMS-BICALUTAMIDE
50MG · TABLET · PHARMASCIENCE INC
DIN 02275589 · ended Jun 20, 2023 · Disruption of the manufacture of the drug.
Resolved
PMS-BICALUTAMIDE
50MG · TABLET · PHARMASCIENCE INC
DIN 02275589 · ended Jun 6, 2023 · Disruption of the manufacture of the drug.
Resolved
TEVA-BICALUTAMIDE
50MG · TABLET · TEVA CANADA LIMITED
DIN 02270226 · ended Apr 27, 2023 · Disruption of the manufacture of the drug.
Resolved
JAMP-BICALUTAMIDE
50MG · TABLET · JAMP PHARMA CORPORATION
DIN 02357216 · ended Oct 21, 2022 · Disruption of the manufacture of the drug.
Discontinued
APO-BICALUTAMIDE
50MG · TABLET · APOTEX INC
DIN 02296063
Resolved
TEVA-BICALUTAMIDE
50MG · TABLET · TEVA CANADA LIMITED
DIN 02270226 · ended Nov 11, 2020 · Disruption of the manufacture of the drug.
Showing 12 of 28 reports. All reports are on file with Health Canada.
What's happening
Bicalutamide is currently affected by an active shortage report filed with Health Canada by ACCORD HEALTHCARE INC.
The reported cause is: disruption of the manufacture of the drug. Manufacturers must report shortages, but end-date estimates are their own projections and often move.
If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.
Bicalutamide is classified under “HORMONE ANTAGONISTS AND RELATED AGENTS” (ATC L02BB).
Recent changes
No changes recorded yet.
Common questions
What is Bicalutamide used for?
A hormone therapy used to treat prostate cancer.
When will Bicalutamide be back in stock in Canada?
Manufacturers have not provided a reliable end date. This page updates automatically as soon as an estimate is filed.
Why is Bicalutamide in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Email alerts
Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.
Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.